Sort   by:  
 Page size 

BACKGROUND: Metabolomic characterization of tumours can potentially improve prediction of cancer prognosis and treatment response. Here, we describe efforts to validate previous metabolomic findings using a historical cohort of breast cancer patients and discuss challenges with u...

2022-01-24 | MTBLS1355 | MetaboLights
This study involves the analysis of surgically resected samples from patients undergoing breast surgery. The samples published here have been used as part of the publication by [1], and all experimental details can be found within. Desorption electrospray ionisation mass spectrometry imaging (DESI M...
2016-04-28 | MTBLS273 | MetaboLights
Invasive ductal carcinoma (IDC) is the most common type of breast cancer and the leading cause of breast cancer related mortality. In the present study, metabolomic profiles of 72 tissue samples and 146 serum samples were analysed using targeted liquid chromatography multiple reaction monitoring mas...
2018-10-16 | MTBLS552 | MetaboLights
Not available
ORGANISM(S): Homo sapiens 

Lipid metabolism drives cancer progression but is difficult to model using conventional methods. In vivo models provide circulating lipids, but are costly and low throughput, while in vitro models lack sufficient lipid availability in culture media. Here, we evaluate the chick chorioallantoic mem...

2026-07-16 | MTBLS13377 | MetaboLights
1H NMR is used to detect alterations in metabolites and their linkage to metabolic processes in a number of pathological conditions including breast cancer. Inositol 1, 4, 5 trisphosphate (IP3R) receptor is an intracellular calcium channel known to regulate metabolism and cellular bioenergetics. Its...
2017-07-18 | MTBLS326 | MetaboLights
An antipsychotic drug, Thioridazine has been shown to inhibit a broad spectrum of cancer cells. However, its molecular mechanism is still not well understood. In the present study, we have shown that thioridazine induces cytostatic effects in both parental and tamoxifen-resistant cancer cells throug...
2025-02-20 | MTBLS11870 | MetaboLights
Changes in cellular lipid metabolism are a common feature in most solid tumors, which occur already in early stages of the tumor progression. However, it remains unclear if the tumor-specific lipid changes can be detected at the level of systemic lipid metabolism. The objective of this study was to ...
2014-06-17 | MTBLS92 | MetaboLights
BACKGROUND: Ductal carcinoma in situ (DCIS) is the earliest stage of breast cancer. During DCIS, tumor cells remain inside the mammary duct, growing under a microenvironment characterized by hypoxia, nutrient starvation, and waste product accumulation; this harsh microenvironment promotes genomic in...
2019-02-08 | MTBLS669 | MetaboLights

Metastatic breast tumors must adapt to the metabolic constraints of their target tissues. To understand how tumor metabolism varies across sites, we compared glucose utilization in primary mammary fat pad (MFP) tumors and brain metastases derived from the breast cancer cell line MDA-MB-231. Tumor...

2025-12-30 | MTBLS13152 | MetaboLights
Sort   by:  
 Page size